Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: A critical comment

Journal of Clinical Pathology

Volumn 50, Issue 8, 1997, Pages 654-660

  Nickels, A ^a   Selter, H ^a   Pfreundschuh, M ^a   Montenarh, M ^a   Koch, B ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Immunological detection; p53; Rheumatoid arthritis

Indexed keywords

PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; FLOW CYTOMETRY; GENE LOCATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RHEUMATOID ARTHRITIS; SYNOVIUM; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR GENE;

EID: 0030882558     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.8.654     Document Type: Article

References (47)

1. Götz C, Montenarh M. p53: DNA-damage, DNA repair and apoptosis. Rev Physiol Biochem Pharmacol 1995;127:65-95.
2. Montenarh M. Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53. In: Critical reviews in ontogenesis. Boca Raton: CRC Press. 1992:233-56.
3. Harris CC. The 1995 Walter Hubert lecture - Molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 1996;73:261-9.
4. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992;89:7262-6.
5. Knippschild U, Oren M, Deppert W. Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion. Oncogene 1996;12:1755-65.
6. Burk U, Selter H, Zwergel T, Wullich B, Montenarh M, Unteregger G. Different subcellular localization of wild-type and mutant p53 in prostate cancer cells. Int J Oncol 1995;7:1355-60.
7. Bartkova J, Bartek J, Vojtesek B, Lukas J, Rejthar A, Kovarik J, et al. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer 1993;29A:881-6.
8. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992;340:259-63.
9. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
10. Voelkerding KV, Steffen DW, Zaidi SHE, Malter JS. Post-transcriptional regulation of the p53 tumor suppressor gene during growth-induction of human peripheral blood mononuclear cells. Oncogene 1995;10:515-21.
11. Osipovich OA, Misuno NI, Kolesnikova TS, Sudarikov AB, Voitenok NN. The difference in p53 antioncogene transcription in human monocytes and lymphocytes. Oncogene 1992;7:549-52.
12. Pezzella F, Micklem K, Turley H, Pulford K, Jones M, Kocialkowski S, et al. Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol 1994;47:592-6.
13. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, et al. p53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 1992;166:235-41.
14. Mateo MS, Sanchez-Beato M, Martinez JC, Orfao A, Orradre JL, Piris MA, et al. p53, Rb and bcl-2 expression during the cell cycle: a study in phytohaemagglutinin stimulated lymphocytes and microwave irradiated lymphoid tissue sections. J Clin Pathol 1995;48:151-59.
15. Martinez JC, Mateo M, Sanchez-Beato M, Villuendas R, Orradre JL, Algara P, et al. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J Pathol 1995;177:27-34.
16. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-4.
17. Imatani A, Sasano H, Yabuki N, Kato K, Ohara S, Asaki S, et al. In situ analysis of tissue dynamics and p53 expression in human gastric mucosa. J Pathol 1996;179:39-42.
18. Spandau DF. Distinct conformations of p53 are observed at different stages of keratinocyte differentiation. Oncogene 1994;9:1861-8.
19. Helander SD, Peters MS, Pittelkow MR. Expression of p53 protein in benign and malignant epidermal pathologic conditions. J Am Acad Dermatol 1993;29:741-8.
20. Hall PA, McKee PH, Du P, Menage H, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993;8:203-7.
21. Szekely L, Pokrovskaja K, Jiang WQ, Selivanova G, Löwbeer M, Ringertz N, et al. Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their Rb, p53 and EBNA-5 expression patterns. Oncogene 1995;10:1869-74.
22. Bi S, Lanza F, Goldman JM. The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res 1994;54:582-6.
23. Kulju KS, Lehman JM. Increased p53 protein associated with aging in human diploid fibroblasts. Exp Cell Res 1995; 217:336-45.
24. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
25. Burmester GR, Locher P, Koch B, Winchester RJ, Dimitriu-Bona A, Kalden JR, et al. The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. Rheumatol Int 1983;3:173-81.
26. Koch B, Locher P, Burmester GR, Mohr W, Kalden JR. The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. II. Rheumatol Int 1984;4:79-85.
27. Fitzgerald O, Soden M, Yanni G, Robinson R, Bresnihan B. Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis 1991;50:792-6.
28. Lalor PA, Mapp PI, Hall PA, Revell PA. Proliferative activity of cells in the synovium as demonstrated by a monclonal antibody, Ki67. Rheumatol Int 1987;7:183-6.
29. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995;96:1631-8.
30. Negoescu A, Labat-Moleur F, Lorimier P, Lamarcq L, Guillermet C, Chambaz E, et al F(ab) secondary antibodies: a general method for double immunolabeling with primary antisera from the same species. Efficiency control by chemiluminescence. J Histochem Cytochem 1994;42:433-37.
31. Eyler YL, Lantz LM, Lewis Jr AM. Flow cytometric detection of DNA tumor virus nuclear oncogene products in unfixed cells: saponin FACS of viral oncogene products. J Virol Meth 1994;46:23-7.
32. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-602.
33. + conformation of wild type p53 binds DNA. Oncogene 1996;13:1297-303
34. Harlow E, Crawford LV, Pim DC, Williamson NM. Monoclonal antibodies specific for the SV40 tumor antigens. J Virol 1981;39:861-9.
35. Banks L, Matlashewski G, Crawford LV. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159: 529-34.
36. Ball RK, Siegl B, Quellhorst S, Brandner G, Braun DG. Monoclonal antibodies against simian virus 40 nuclear large tumour antigen: epitope mapping, papova virus cross-reaction and cell surface staining. EMBO J 1984;3: 1485-91.
37. Milner JA, Cook A, Sheldon M. A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene 1987;1:453-5.
38. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
39. Milner J. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 1984;310:143-5.
40. Said JW, Barrera R, Shintaku IP, Nakamura H, Koeffler HP. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol 1992;141:1343-8.
41. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 1994;144:573-84.
42. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 1993;143:845-56.
43. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinez JC, et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993;82:3151-6.
44. Speir E, Huang ES, Modali R, Leon MB, Shawl F, Finkel T, et al. Interaction of human cytomegalovirus with p53: possible role in coronary restenosis. Scand J Infect Dis 1995;99(Suppl):78-81.
45. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993;8:289-8.
46. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, et al. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 1990;46:839-44.
47. Strang P, Nordström B, Nilsson S, Bergström R, Tribukait B. Mutant p53 protein as a predictor of survival in endometrial carcinoma. Eur J Cancer 1996;32A:598-602.